Real-world Treatment of H. Pylori Eradication in Patients with Comorbidity

CompletedOBSERVATIONAL
Enrollment

1,053

Participants

Timeline

Start Date

May 6, 2020

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions
Helicobacter Pylori InfectionComorbidities and Coexisting ConditionsReal-world OutcomeMedication AdherencePatient CompliancePatient Dropouts
Interventions
DRUG

The sequential therapy

Proton pump inhibitors and amoxicillin for the first 5 or 7 days and sequent proton pump inhibitors, clarithromycin, and metronidazole for the next 5 or 7 days

DRUG

The triple therapy

Proton pump inhibitors, amoxicillin, and clarithromycin for 7, 10, or 14 days.

DRUG

The hybrid therapy

Proton pump inhibitors and amoxicillin starting from the 1st day and for a total of 10 or 14 days, and clarithromycin, and metronidazole starting from the 8th day and for a total of 7 days .

DRUG

The concomitant therapy

Proton pump inhibitors, amoxicillin, clarithromycin, and metronidazole for a total of 7 or 14 days

DRUG

Bismuth-based quadruple therapy

Proton pump inhibitors, bismuth, tetracycline, and metronidazole for a total of 10 or 14 days

Trial Locations (2)

70403

Helicobacter pylori study group, National Cheng Kung University Hospital, Tainan City

704302

National Cheng Kung University Hospital, Tainan City

All Listed Sponsors
collaborator

Ministry of Health and Welfare, Taiwan

OTHER_GOV

lead

National Cheng-Kung University Hospital

OTHER

NCT05475431 - Real-world Treatment of H. Pylori Eradication in Patients with Comorbidity | Biotech Hunter | Biotech Hunter